ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting

    A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

    Liqin Wang1, Eli Miloslavsky 2, John Stone 3, Hyon K. Choi 4, Li Zhou 5 and Zachary Wallace 2, 1Brigham and Women's Hospital, Boston, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death.  Retrospective studies on the clinical course of AAV, including the…
  • Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting

    ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

    Laura van Dam1, Ebru Dirikgil 2, Edwin Bredewold 2, Argho Ray 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
  • Abstract Number: 1678 • 2019 ACR/ARP Annual Meeting

    Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis

    Haidy Adel Youssef1 and Mehrnaz Hojjati 2, 1Riverside Community Hospital/ UCR School of Medicine Internal Medicine Residency Program, Corona, CA, 2Department of Rheumatology, Loma Linda University, Loma Linda, CA

    Background/Purpose: ANCA associated vasculitis patients have a wide spectrum of pulmonary involvement in the form nodular disease (especially peri-bronchial nodules), cavitating lesions, diffuse alveolar hemorrhage and less…
  • Abstract Number: 2637 • 2019 ACR/ARP Annual Meeting

    Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis

    Salem Almaani1, Christopher Toy 2, Anna Levesque 2, Lynn Fussner 1, Alexa Meara 1, Lianbo Yu 1, David Cuthbertson 3, Simon Carette 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol Langford 7, Carol A. McAlear 8, Larry Moreland 9, Christian Pagnoux 10, Philip Seo 11, Antoine Sreih 12, Steven Ytterberg 13, Paul Monach 14, Peter Merkel 12, Brad Rovin 1 and Dan Birmingham 15, 1The Ohio State University Medical Center, Columbus, OH, 2Ohio State University, Columbus, OH, 3University of South Florida, Tampa, FL, 4Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 5McMaster University, Hamilton, ON, Canada, 6University of Utah Hospital, Salt Lake City, UT, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 9University of Pittsburgh, PITTSBURGH, PA, 10Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 11Johns Hopkins Medicine, Baltimore, MD, 12University of Pennsylvania, Philadelphia, PA, 13Mayo Clinic College of Medicine, Rochester, MN, 14Brigham and Women's Hospital, Boston, MA, 15The Ohio State University Medical Center, Columbus

    Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV).  Change in markers of complement activation within patients have not…
  • Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting

    Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Peter Merkel1, Bernhard Hellmich 2, David Jayne 3, Simon Rückinger 4, Zsuzsanna Tamas 5, Claus Thielert 5 and Othmar Zenker 6, 1University of Pennsylvania, Philadelphia, PA, 2Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, 3Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 4Metronomia Clinical Research GmbH, Munich, Germany, 5InflaRx GmbH, Planegg, Germany, 6InflaRx GmbH, Jena, Germany

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
  • Abstract Number: 2642 • 2019 ACR/ARP Annual Meeting

    ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA

    ‪Gabriel Breuer‬‏1, Bashar Fteiha 1, Alon Benaya 1, Marwan Abu Sneineh‬‏ 1 and Gideon Nesher 1, 1Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel

    Background/Purpose: With the widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. In addition to ANCA Associated Vasculitis (AAV),…
  • Abstract Number: 806 • 2019 ACR/ARP Annual Meeting

    A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease

    Rona Smith1, David Jayne 2 and Peter Merkel 3, 1University of Cambridge, Cambridge, England, United Kingdom, 2Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia

    Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV).  However, the effect of rituximab is not sustained, and relapse rates…
  • Abstract Number: 1680 • 2019 ACR/ARP Annual Meeting

    Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis

    Peter Merkel1, Bernhard Hellmich 2, David Jayne 3, Simon Rückinger 4, Zsuzsanna Tamas 5, Claus Thielert 5 and Othmar Zenker 6, 1University of Pennsylvania, Philadelphia, PA, 2Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, 3Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 4Metronomia Clinical Research GmbH, Munich, Germany, 5InflaRx GmbH, Planegg, Germany, 6InflaRx GmbH, Jena, Germany

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Standard of care (SOC)…
  • Abstract Number: 2643 • 2019 ACR/ARP Annual Meeting

    Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre

    Lara Sanchez-Bilbao1, Marina De Cos-Gomez 2, Iñigo Gonzalez-Mazon 3, Belén Atienza-Mateo 1, Jose Luis Martín-Varillas 1, Mónica Calderón-Goercke 4, DIANA PRIETO- PENA 3, Juan Carlos Ruiz-San Millan 2, Miguel A Gonzalez-Gay 1 and Ricardo Blanco 1, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Nephrology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized clinically by a rapid and severe decline in kidney function. Thus, this entity may lead to an end…
  • Abstract Number: 871 • 2019 ACR/ARP Annual Meeting

    ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

    Zachary Wallace1, Huifeng Yun 2, Jeffrey Curtis 2, Shuo Yang 2, Lang Chen 2, John Stone 3 and Hyon K. Choi 4, 1Massachusetts General Hospital, Boston, 2University of Alabama at Birmingham, Birmingham, AL, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens.  As such, treatment…
  • Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting

    The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

    Zachary Wallace1, Xiaoqing Fu 1, Yuqing Zhang 2, John Stone 3 and Hyon K. Choi 2, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state.  AAV patients are at a 2-fold higher risk of cardiovascular…
  • Abstract Number: 2786 • 2019 ACR/ARP Annual Meeting

    Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure

    Dorian Nezam 1, Pauline Morel 1, Stanislas Faguer 2, Alexandre Karras 3, Julien Aniort 4, Dimitri Titeca-Beauport 5, Justine Solignac 6, Didier Ducloux 7, Rafik Mesbah 8, Pierre-Louis Carron 9, Cédric Rafat 10, Pierre Gobert 11, Vincent Audard 12, Séverine Beaudreuil 13, François Maurier 14, Nihal Martis 15, Aurélien Tiple 4, Stéphane Bally 16, Aurélie Hummel 17, Claire de Moreuil 18, Tiphaine Goulenok 17, Dominique Nochy 19, Noémie Jourde-Chiche 20, Alexis Régent 21, Loic Guillevin 21 and Benjamin Terrier21, 1Cochin Hospital, Paris, France, 2CHU Toulouse, Toulouse, France, 3Paris HEGP, Paris, France, 4CHU, Clermont-Ferrand, France, 5CHU, Amiens, France, 6CHU, Marseille, France, 7CHU, Besancon, France, 8CH, Boulogne sur Mer, France, 9Grenoble, Grenoble, France, 10Tenon Hospital, Paris, France, 11Clinique Rhone Durance, Avignon, France, 12Henri Mondor Hospital, Créteil, France, 13Bicetre Hospital, Le Kremlin Bicetre, France, 14Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, 15CHU, Nice, France, 16CH, Chambery, France, 17APHP, Paris, France, 18CHU Brest, Brest, France, 19HEGP Hospital, Paris, France, 20APHM, Marseille, Marseille, France, 21National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France

    Background/Purpose: ANCA-associated vasculitides (AAVs) are the most frequent cause of rapidly progressive glomerulonephritis (RPGN), for which the major prognostic issue is the risk of developing…
  • Abstract Number: 874 • 2019 ACR/ARP Annual Meeting

    Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features

    Iazsmin Ventura1, Anisha Dua 2, Ayodeji Adegunsoye 3, Mary Strek 3, James Curran 1, Alexandra Weiss 1 and Jonathan Chung 1, 1University of Chicago, Chicago, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of Chicago, Department of Pulmonary and Critical Care, Chicago

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…
  • Abstract Number: 1682 • 2019 ACR/ARP Annual Meeting

    Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States

    Patompong Ungprasert1, Matthew Koster 2, Wisit Cheungpasitporn 3, Karn Wijarnpreecha 4, Charat Thongprayoon 2 and Paul Kroner 5, 1Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, 2Mayo Clinic Rochester, Rochester, MN, 3University of Mississippi Medical Center, Jackson, MS, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic Florida, Jacksonville

    Background/Purpose: Granulomatosis with polyangiitis (GPA, formerly known and Wegener’s granulomatosis) is a major subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by granulomatous inflammation of…
  • Abstract Number: 2787 • 2019 ACR/ARP Annual Meeting

    Predictors of Renal Involvement in ANCA-Associated Vasculitis

    Andreas Kronbichler 1, Jae Il Shin 2, Keum Hwa Lee 2, Daiki Nakagomi 3, Luis Quintana 4, Martin Busch 5, Anthea Craven 6, Raashid Luqmani 6, Peter Merkel7, Gert Mayer 1, David Jayne 8 and Richard Watts 9, 1Medical University Innsbruck, Innsbruck, Austria, 2Yonsei University College of Medicine, Seoul, Republic of Korea, 3University of Yamanashi, Yamanashi, Japan, 4University of Barcelona, Barcelona, Spain, 5University of Jena, Jena, Germany, 6University of Oxford, Oxford, United Kingdom, 7University of Pennsylvania, Philadelphia, PA, 8Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 9University of East Anglia, Norwich, United Kingdom

    Background/Purpose: Renal involvement in the context of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is associated with significant morbidity and higher mortality rates. This study examined…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology